Valuation : Incyte Corporation

Market Cap 25.97B 134B 22.29B 20.92B 19.11B 36.06B 2,477B 36.24B 248B 95.95B 1,250B 97.51B 95.39B 4,139B P/E 2026 *
57.2x
P/E 2027 * 17.7x
Enterprise Value 21.74B 112B 18.66B 17.51B 16B 30.19B 2,074B 30.33B 207B 80.32B 1,046B 81.63B 79.86B 3,465B EV / Sales 2026 *
3.66x
EV / Sales 2027 * 3.19x
Free-Float
98.16%
Yield 2026 *
-
Yield 2027 * -
1 day-0.20%
1 week+5.32%
Current month+7.32%
1 month+11.19%
3 months+36.27%
6 months+28.87%
Current year+18.38%
1 week 327.36
Extreme 327.36
328.68
1 month 296.88
Extreme 296.88
328.68
Current year 232.56
Extreme 232.56
328.68
1 year 222.86
Extreme 222.86
328.68
3 years 135.9
Extreme 135.9
328.68
5 years 135.9
Extreme 135.9
328.68
10 years 135.9
Extreme 135.9
328.68
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%+5.32% - - 25.97B
-2.25%-3.10%+38.65%-1.87% 81.36B
-5.77%-14.18%+505.18%+33.71% 59.75B
+0.84%+4.44%-19.19%-35.11% 59.19B
+0.76%+3.53%+0.08%+36.18% 53.33B
+1.18%+2.62%+11.13%+172.09% 49.09B
+0.14%-0.22%+61.70%-16.40% 32.66B
-1.23%-0.27%+52.52%+100.63% 25.97B
-2.00%+6.32%+18.24%+209.64% 24.39B
+0.88%+0.60%+61.74%+123.69% 16.91B
Average -0.70%+0.16%+81.12%+69.17% 44.74B
Weighted average by Cap. -0.95%-1.01%+93.41%+48.29%

Financials

2026 *2027 *
Net sales 5.94B 30.66B 5.1B 4.79B 4.37B 8.25B 567B 8.29B 56.65B 21.95B 286B 22.31B 21.83B 947B 6.27B 32.33B 5.38B 5.05B 4.61B 8.7B 598B 8.74B 59.73B 23.15B 301B 23.52B 23.01B 998B
Net income 466M 2.4B 400M 375M 343M 647M 44.43B 650M 4.44B 1.72B 22.41B 1.75B 1.71B 74.24B 1.5B 7.72B 1.28B 1.21B 1.1B 2.08B 143B 2.09B 14.26B 5.53B 71.98B 5.62B 5.49B 238B
Net Debt -4.23B -21.82B -3.63B -3.41B -3.11B -5.87B -403B -5.9B -40.32B -15.63B -204B -15.88B -15.54B -674B -5.99B -30.91B -5.14B -4.83B -4.41B -8.32B -571B -8.36B -57.12B -22.13B -288B -22.49B -22.01B -955B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change
24/08/26 R$328.02 -0.20%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
128.12USD
Average target price
127.12USD
Spread / Average Target
-0.78%

Quarterly revenue - Rate of surprise